Browse by author
Lookup NU author(s): Professor Nick ReynoldsORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2025 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. Background: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE). Objectives: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe. Methods: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium). Results: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4. Conclusions: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.
Author(s): Musters AH, Gerbens LAA, van der Gang L, Middelkamp-Hup MA, Ouwerkerk W, Hijnen DJ, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, Svedbom A, Johansson EK, Bradley M, von Kobyletzki LB, Vittrup I, Ruge IF, Thyssen JP, Vestergaard C, Carrascosa JM, de Vega M, Garcia-Doval I, Chiricozzi A, Stingeni L, Calzavara-Pinton P, Ardern-Jones MR, Reynolds NJ, Flohr C, Spuls PI, Bosma A, Caron A, Hyseni A, Dijkstra J, Nguyen L, De Schepper S, Lapeere H, De Waele D, Beattie P, Brown S, Burton T, Ingram J, Irvine A, Johnston G, Man I, Manca A, Ogg G, Patton T, Wan M, Warren R, Woolf R, Baden M, Prieto-Merino D, Malik R, Coker B, De La Cruz L, Gribaleva E, Begum T, Descalzo MA, Florez A, Arnau AMG, Quesada AG, Silvestre JF, Serna MR, Chicharro P, Gilaberte Y, de la Cueva P, Montero T, Gonzalez ME, Villaverde RR, Rodriguez JJP, Cebey AB, Arias ME, Rodriguez CC, Curto L, Bertolin M, Castano I, Betlloch I, Perez MAL, Perez JAS, Ruiz AB, Munera M, Arias-Santiago S, Roustan G, de la Torre RS, Diaz AR, Carrascosa JCR, Navarro Trivino FJ, Elberling J, Skov L, Ibler K, Jemec G, Moertz C, Bindslev-Jensen C, Kamstrup M, Egeberg A, Deleuran M, Alsterholm M, Anderson CD, Bradley M, Sommar LH, Ivert L, Johansson EK, Josefson A, Lundeberg L, Lundqvist M, Nylander E, Sandstrom-Falk M, Shayesteh A, Sigurdardottir G, Sonesson A, Svedbom A, Svensson A, Virtanen M, von Kobyletzki L, Vrang S, Wahlgren C-F, Corazza M, Esposito M, Fabbrocini G, Fargnoli MC, Ferrucci SM, Foti C, Girolomoni G, Hansel K, Marzano AV, Napolitano M, Passante M, Patruno C, Peris K, Pigatto PD, Romanelli M, Romita P, Rossi M, Schena D, Schettini N, Tonini G
Publication type: Article
Publication status: Published
Journal: Journal of the European Academy of Dermatology and Venereology
Year: 2025
Volume: 39
Issue: 12
Pages: 2096-2112
Print publication date: 01/12/2025
Online publication date: 20/08/2025
Acceptance date: 09/06/2025
Date deposited: 04/09/2025
ISSN (print): 0926-9959
ISSN (electronic): 1468-3083
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1111/jdv.20876
DOI: 10.1111/jdv.20876
Data Access Statement: The authors confirm that the data supporting the findings of this study are available within the article.
Altmetrics provided by Altmetric
